Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Astex, Novartis ally in developing oncology drugs

Executive Summary

Novartis licensed worldwide development and commercialization rights to Astex's preclinical oral cell cycle inhibitor AT9311, and gets the option to license its AT7519, a Phase I parenteral cell cycle inhibitor. Both compounds are being studied as potential treatments for solid tumors.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Includes Equity

Related Companies

UsernamePublicRestriction

Register